Lo Serigne N, Williams Gabrielle J, Cust Anne E, Varey Alexander H R, Ch'ng Sydney, Scolyer Richard A, Thompson John F
Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales (NSW), Australia.
Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia.
J Natl Cancer Inst. 2025 Jan 1;117(1):152-156. doi: 10.1093/jnci/djae198.
The prognosis of a patient with a primary cutaneous melanoma is known to be related to the Breslow thickness of their tumor. This study sought to determine long-term (30-year) survival rates for the 4 American Joint Committee on Cancer 8th edition T categories by analyzing Australian registry data for 210 042 melanoma patients diagnosed from 1982 to 2014. The 30-year incidence rates of death due to melanoma and nonmelanoma (with 95% confidence intervals [CIs]) were 7.1% (95% CI = 6.9% to 7.3%) and 32.8% (95% CI = 32.3% to 33.3%), respectively. For T2 melanomas, the corresponding rates were 21.6% (95% CI = 21.0% to 22.3%) and 35.6% (95% CI = 34.7% to 36.6%), for T3 melanomas 34.2% (95% CI = 33.4% to 35.1%) and 39.6% (95% CI = 38.5% to 40.8%), and for T4 melanomas 44.3% (95% CI = 43.2% to 45.3%) and 39.6% (95% CI = 38.3% to 41.0%). A plateau in melanoma-related deaths occurred in T4 patients after 20 years, but there were ongoing melanoma-related deaths for the other T categories beyond 30 years. A progressive rise in the risk of death from other causes occurred across all T categories.
已知原发性皮肤黑色素瘤患者的预后与肿瘤的 Breslow 厚度有关。本研究旨在通过分析 1982 年至 2014 年确诊的 210042 例黑色素瘤患者的澳大利亚登记数据，确定美国癌症联合委员会第 8 版 4 个 T 分期类别的长期（30 年）生存率。黑色素瘤和非黑色素瘤导致的 30 年死亡率（95%置信区间[CI]）分别为 7.1%（95%CI = 6.9%至 7.3%）和 32.8%（95%CI = 32.3%至 33.3%）。对于 T2 期黑色素瘤，相应的死亡率分别为 21.6%（95%CI = 21.0%至 22.3%）和 35.6%（95%CI = 34.7%至 36.6%）；对于 T3 期黑色素瘤，分别为 34.2%（95%CI = 33.4%至 35.1%）和 39.6%（95%CI = 38.5%至 40.8%）；对于 T4 期黑色素瘤，分别为 44.3%（95%CI = 43.2%至 45.3%）和 39.6%（95%CI = 38.3%至 41.0%）。T4 期患者在 20 年后黑色素瘤相关死亡出现平台期，但其他 T 分期类别在 30 年后仍有持续的黑色素瘤相关死亡。所有 T 分期类别中，其他原因导致的死亡风险均呈逐渐上升趋势。
